The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.

This prospective double-blind randomized control trial seeks to compare a single formulation of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of BoNT on Raynaud's symptoms among a more diverse population to provide insight into the patients most likely to benefit from BoNT.

Inclusion Criteria:

• Male or female adult between 18 and 80 years of age
• Must have health insurance
• Must have a current diagnosis of Raynaud's phenomenon

Exclusion Criteria:

• Allergy to abobotulinum toxin A or its components
• Diagnosis of myasthenia gravis
• Previously received abobotulinum toxin vaccine
• Previously undergone upper extremity vascular surgery (including surgical sympathectomy)
• Currently receiving aminoglycoside antibiotics
• Received abobotulinum toxin A treatment in either hand in the past 6 months
• Pregnant women
• Women currently breastfeeding
• Current tobacco smoker (use in the past 12 months)
• Unable to read and speak English
• Adults unable to consent
• Individuals who are not yet adults (infants, children, teenagers)
• Prisoners